XBiotech Inc. XBIT Cash Flow

Xbiotech inc. (XBIT)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14
Operating activities
Net loss
-14	686,495	-6,150	-5,852	-5,864	-6,111	-5,051	-5,907	-4,069	-7,249	-6,205	-9,133	-10,563	-16,398	-12,484	-13,622	-10,257	-11,889	-10,736	-6,744	-8,114	-6,352	-6,962	-3,907	-4,503
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
558	566	596	597	602	617	618	610	588	595	297	296	296	173	175	171	179	189	169	176	165	231	146	146	141
Share-based compensation expense
3,456	1,505	797	486	570	474	439	637	110	410	444	172	724	1,533	1,126	1,097	1,817	1,052	886	1,247	1,222	2,048	2,524	606	1,842
Account receivable
9,681	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred cost of goods sold
1,703	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income tax receivable
3,793	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
-489	1,092	-105	-285	-230	736	-461	-415	-232	253	-39	-880	-375	559	518	-52	-408	83	-1,064	2,478	82	37	33	66	-174
Accounts payable
3,470	1,088	-380	-311	99	775	-578	321	-596	-493	-1,040	668	-1,835	1,093	-3,610	3,884	-2,348	-284	980	-739	883	351	287	610	-180
Accrued expenses
-2,815	3,219	48	-68	-311	-131	120	28	212	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-3,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued expenses
-	-	-	-	-	-	-	-	-	-	0	-1,349	-905	1,356	294	166	250	472	413	-330	-607	308	809	-70	187
Deferred rent
-	-	-	-	-3	-	-	-	-3	-2	-1	-2	0	1	1	1	4	5	5	5	2	-	-	-	-
Tax payable
-47,640	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-60,673	-3,746	-4,984	-4,863	-4,677	-5,116	-3,995	-3,900	-3,526	-6,807	-6,466	-8,468	-11,908	-	-	-	-9,947	-10,695	-7,219	-8,863	-6,531	-3,451	-3,229	-2,681	-2,339
Investing activities
Purchase of property and equipment
389	6	161	31	6	8	32	48	34	254	261	283	607	531	613	2,059	1,543	363	1,233	574	152	579	515	245	58
Expenditure on building construction
-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,559	3,798	1,374	-	-	-	-	-	-	-	-
Expenditures on building construction
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,383	3,203	1,065	419	-	-	-	-
Net cash used in investing activities
-389	674,994	-161	-31	-6	-8	-32	-48	-34	-254	-261	-283	-607	-	-	-	-2,917	-3,746	-4,436	-1,639	-571	-551	-529	-259	-58
Financing activities
Share repurchases of common stock and warrants, net
-420,000	-	-	-	541	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of common stock and warrants, net
-	-	-	-	-	-	-	-	-	-	0	0	32,620	1,808	0	0	0	-343	30	73,624	2,401	46,023	5,746	0	11,605
Issuance of common stock under stock option plan
7,918	2,597	298	637	200	-	-	-	201	4	45	561	93	270	159	707	0	670	0	670	8	-	-	-	-
Collection of subscription receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	410	-	-	-	-
Deferred offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-1,037	712	-	-	-	-
Net cash provided by (used in) financing activities
-412,082	3,172	288	37,895	741	0	0	0	201	4	45	561	32,713	-	-	-	0	2	30	75,331	2,107	45,849	5,746	0	11,605
Effect of foreign exchange rate on cash and cash equivalents
90	-164	274	-99	138	98	27	381	7	-152	-290	-493	110	222	24	-26	38	-190	-77	317	-98	-14	99	-17	-86
Net change in cash and cash equivalents
-473,054	674,256	-4,583	32,902	-3,804	-5,026	-4,000	-3,567	-3,352	-7,209	-6,972	-8,683	20,308	-12,469	-18,005	-13,427	-12,826	-14,629	-11,702	65,146	-5,093	41,833	2,087	-2,957	9,122
Supplemental Information:
Accrued purchases of property and equipment
32	-	-	0	109	-	-	-	25	-	-	21	101	-298	-135	176	405	762	-54,063	-349,787	404,028	-	-	-	-
Accrued expenditures on building construction
-	-	-	-	-	-	-	-	-	-	-	-	-	-828	-283	-413	1,963	382	1,034	0	0	-	-	-	-
Subscription receivable
-	-	-	-	102	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivable on issuance of common stock under stock option plan
-	-	-	-	-	-	-	-	-	-	-	-	223	-	-	-	0	-	-	-	-	-	-	-	-